10-Q: GB Sciences Reports Q1 2025 Results, Focuses on Drug Development and Intellectual Property

Sentiment:

Quarterly Report 27 November 2024 1:45 PM

GB Sciences reports a net loss for the quarter ended June 30, 2024, while continuing to advance its drug development programs and intellectual property portfolio.

Capital raiseThe company states it will need to raise additional capital by the end of the next quarter in order to continue to fund current operations.The company is pursuing several alternatives to address this situation, including the raising of additional funding through equity or debt financing.The company states it will likely require the sale of additional common stock or other securities.

Worse than expectedThe company's net loss and working capital deficit are worse than expected, indicating financial challenges.The company's cash balance of $0 is worse than expected, raising concerns about its ability to continue operations.

Summary

GB Sciences, a biopharmaceutical research and development company, reported a net loss of $285,018 for the quarter ended June 30, 2024, compared to a net loss of $273,121 for the same period in 2023.
The company's general and administrative expenses decreased slightly to $254,137 from $265,122 year-over-year.
Interest expense decreased to $30,881 from $40,804 in the prior year quarter, due to debt discounts becoming fully amortized.
The company's cash balance is $0, and it has a working capital deficit of $5,267,133.
GB Sciences is focused on developing plant-inspired medicines, with a portfolio of intellectual property including eight U.S. and twelve foreign patents issued, two foreign patents allowed, as well as fifteen U.S. and forty-one foreign patent-pending applications.
The company is actively seeking licensing partners to support the development of its Parkinson's disease therapy and other drug programs.
GB Sciences has completed several preclinical studies with positive results for its Parkinson's disease, chronic pain, anxiety, and cytokine release syndrome therapies.
The company has a licensing agreement with EndoPure Life Sciences, LLC, where EndoPure will pay royalties and upfront payments to license certain intellectual property rights from GB Sciences.

Sentiment

Score: 3

Explanation: The document presents a challenging financial situation with significant losses, a large working capital deficit, and a cash balance of zero. While there are positive aspects such as the intellectual property portfolio and preclinical progress, the financial risks and going concern uncertainty dominate the overall sentiment.

Positives

GB Sciences has a strong intellectual property portfolio with numerous patents and pending applications.
The company has made progress in preclinical studies for its various drug programs, including Parkinson's disease, chronic pain, and anxiety.
The licensing agreement with EndoPure provides a potential revenue stream and validation of the company's intellectual property.
The company is actively seeking partnerships to advance its drug development programs.
The company has reduced general and administrative expenses compared to the same quarter last year.

Negatives

GB Sciences reported a net loss of $285,018 for the quarter ended June 30, 2024.
The company has a significant working capital deficit of $5,267,133.
The company's cash balance is $0 as of June 30, 2024.
The company has a history of net losses and an accumulated deficit of $110,352,010.
There is substantial doubt about the company's ability to continue as a going concern.
The company has a significant amount of debt, including convertible notes payable.

Risks

The company's ability to continue as a going concern is dependent on obtaining additional financing.
There is no assurance that the company will be able to raise the necessary capital.
The company's drug development programs are subject to regulatory risks and may not be successful.
The company is dependent on third parties for preclinical studies and clinical trials.
The company faces competition from other pharmaceutical companies.
The company has a history of losses and may not achieve profitability.
The company has a significant amount of debt and may not be able to meet its obligations.

Future Outlook

The company expects expenses to increase significantly to grow the business if it is able to obtain the necessary financing. The company anticipates that cash flows from operations will be insufficient to fund business operations for the next twelve-month period and will need to raise additional capital.

Management Comments

Management believes that its current and future plans provide an opportunity to continue as a going concern.
Management has been able, thus far, to finance the losses through debt financing, a public offering, private placements and obtaining operating funds from stockholders.
Management is continuing to seek sources of financing.

Industry Context

GB Sciences operates in the biopharmaceutical industry, focusing on plant-inspired medicines. The company's focus on Parkinson's disease, chronic pain, and other therapeutic areas aligns with significant market needs and growth potential. The company's approach of using AI-enabled drug discovery and targeting specific clinical applications is a trend in the industry.

Comparison to Industry Standards

GB Sciences is a small, development-stage biopharmaceutical company, and its financial results are not directly comparable to large, established pharmaceutical companies.
The company's focus on plant-based therapeutics is a growing area in the industry, but it faces competition from both traditional pharmaceutical companies and other biotech firms.
The company's intellectual property portfolio is a key asset, but its value depends on the successful development and commercialization of its drug candidates.
The company's financial position is weak, with a significant working capital deficit and a history of losses, which is not uncommon for early-stage biotech companies.
The company's reliance on external funding is a risk, as is typical for companies in this sector.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Material Weakness	No member of the board of directors qualifies as an audit committee financial expert.	2024-06-30	This is a material weakness in internal controls.
Material Weakness	The duties of the principal executive officer and the principal financial officer are consolidated in one person, lacking dual control.	2024-06-30	This is a material weakness in internal controls.

Legal Proceedings

The company is involved in a lawsuit filed in the Eighth Judicial District Court in Clark County, Nevada, related to an alleged incident at the Teco Facility in May of 2020.
The company believes it may have coverage under an insurance policy in the event the company is found liable for damages, however, the company denies any liability and intends to vigorously defend the lawsuit.

Related Party Transactions

As of June 30, 2024, $108,816 has been recorded in accounts payable related party, due to an entity controlled by a family member of Mr. John Poss, Chief Executive Officer of the Company.
As of June 30, 2024, $7,634 was owed to Mr. Poss for expenses incurred in connection with the business operations of the Company.
As of June 30, 2024, $18,498 has been recorded in accounts payable related party, due to Dr. Andrea Small Howard, President and Director, related to amounts owed for expenses incurred in connection with the business operations of the Company.

Stakeholder Impact

Shareholders face significant risk due to the company's financial challenges and going concern uncertainty.
Employees may be impacted by potential cost-cutting measures or restructuring.
Customers and suppliers may be affected by the company's ability to continue operations.
Creditors face the risk of non-payment due to the company's financial difficulties.

Next Steps

The company will continue to seek licensing partners for its drug development programs.
The company will continue to advance its preclinical studies for various therapeutic programs.
The company will seek additional financing to fund its operations.
The company will continue to develop, manufacture, and market pharmaceutical products that are protected within GB Sciences IP portfolio through its licensing agreement with EndoPure.

Key Dates

Date	Description
2001-04-04	The company was incorporated in the State of Delaware under the name Flagstick Venture, Inc.
2008-03-28	Stockholders approved changing the name to Signature Exploration and Production Corp.
2014-04-04	The company changed its name to Growblox Sciences, Inc.
2016-12-12	The company changed its name to GB Sciences, Inc.
2017-10-23	The company amended the Nevada Medical Marijuana Production License Agreement and issued a 0% Promissory Note.
2018-04-08	Shareholders approved the change in corporate domicile to Nevada and increased authorized capital shares to 400,000,000.
2019-08-15	Shareholders approved an increase in authorized capital shares to 600,000,000.
2020-03-24	The company entered into the Membership Interest Purchase Agreement (Teco MIPA) to sell its Nevada subsidiaries.
2020-05-19	The company was issued U.S. Patent No. 10,653,640 for cannabinoid-containing complex mixtures for the treatment of neurodegenerative diseases.
2020-08-10	The company entered into the Membership Interest Purchase Agreement (Nopah MIPA) to sell its interest in GB Sciences Nopah, LLC.
2020-12-18	The company began an offering of 6.0% convertible notes.
2021-12-14	The company received approval from the Nevada Cannabis Compliance Board for the transfer of cannabis licenses.
2021-12-31	The sales of the Nevada Subsidiaries formally closed.
2022-03-01	The company's fourth US Patent was issued for a cannabinoid-containing mixture designed to treat cardiac hypertrophy.
2022-03-04	The company entered into the Second Promissory Note Modification Agreement.
2022-12-01	The Israeli (IL) Patent was allowed, protecting the company's Cannabinoid-Containing Complex Mixtures for the treatment of Mast Cell Activation Syndrome (MCAS).
2022-12-15	The Australian (AU) Patent was allowed, protecting the company's Cannabinoid-Containing Complex Mixtures for the treatment of Mast Cell Activation Syndrome (MCAS).
2023-02-03	GB Sciences first foreign patent protecting its proprietary cannabinoid-based formulations for Parkinsons disease was issued in China.
2023-02-20	The Japanese (JP) Patent was allowed, protecting the company's Cannabinoid-Containing Complex Mixtures for the treatment of Mast Cell Activation Syndrome (MCAS).
2023-03-09	Shareholders approved an increase in authorized capital shares to 950,000,000 and the Notice of Allowance was received for the company's U.S. Patent Application No. 16/878,295.
2023-03-27	The company and AJE Management entered into an agreement regarding the note receivable.
2023-04-25	The Japanese patent was also issued for the use of GBSGBs Cannabinoid-Containing Complex Mixtures in the treatment of Parkinsons disease.
2023-09-01	The company extended the expiration date and temporarily repriced 92,657,209 unexpired investor warrants.
2024-01-22	The company offered additional 6% convertible notes to 13 investors.
2024-02-07	The company offered additional 6% convertible notes to 13 investors.
2024-05-16	The company repriced 1,000,000 unexpired investor warrants from $0.10 to $0.01 and the warrants were exercised.
2024-06-30	End of the quarterly period.
2024-09-26	The company entered into a licensing agreement with EndoPure Life Sciences, LLC.
2024-11-27	Date of the report.

Keywords

biopharmaceutical, drug development, intellectual property, patents, Parkinson's disease, chronic pain, cannabinoid, licensing agreement, preclinical studies, financial results

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.